Genkyotex is developing first-in-class, small molecule therapeutics that selectively inhibit the NOX family of enzymes. In humans, these enzymes play an important role in maintaining normal function, but under various conditions they become overactive and lead to disease. Targeting NOX enzymes may lead to more effective medical treatments as they address the source of the disease. By targeting the various forms of the NOX enzyme, Genkyotex is able to develop specific drugs against various diseases.Using a unique proprietary screening platform, Genkyotex has identified novel NOX inhibitors with the potential to treat disease areas with a high clinical need and large market potential. The company’s lead product is GKT137831, a dual inhibitor of NOX4 and NOX1, which is in clinical development for the treatment of diabetic nephropathy.Genkyotex is headquartered in Plan-Les-Ouates near Geneva, Switzerland, with a subsidiary Genkyotex Innovation SAS based in Archamps, France. The Company was founded in 2006 by an international group of scientific experts in the field of free radical generating enzymes with backing from Geneva incubator Eclosion, FAE and Sefti. Subsequently further investment has been provided by Edmond de Rothschild Investment Partners , Vesalius BioCapital, MP Healthcare Venture Management.